Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands

Autor: van den Bogert, Cornelis A., Souverein, Patrick C., Brekelmans, Cecile T.M., Janssen, Susan W.J., Koëter, Gerard H., Leufkens, Hubert G.M., Bouter, Lex M.

Publikováno v: In Journal of Clinical Epidemiology August 2017 88:140-147

Hereditary breast cancer growth rates and its impact on screening policy

Autor: Tilanus-Linthorst, Madeleine M.A., Kriege, Mieke, Boetes, Carla, Hop, Wim C.J., Obdeijn, Inge-Marie, Oosterwijk, Jan C., Peterse, Hans L., Zonderland, Harmine M., Meijer, Sybren, Eggermont, Alexander M.M., de Koning, Harry J., Klijn, Jan G.M., Brekelmans, Cecile T.M.

Publikováno v: In European Journal of Cancer 2005 41(11):1610-1617

Comment on Screening by MRI Mentioned in the Reviews by Narod and Møller

Autor: Kriege Mieke, Brekelmans Cecile TM, Klijn Jan GM

Publikováno v: Hereditary Cancer in Clinical Practice, Vol 2, Iss 1, Pp 17-18 (2004)

Externí odkaz: https://doaj.org/article/f7ff5c64f1be45a1acc9dce2ebe8c464

A family history of breast cancer will not predict female early onset breast cancer in a population-based setting

Autor: Klijn Jan GM, Cornelisse Cees J, van Asperen Christi J, Blom Jannet, Krol-Warmerdam Elly MM, Seynaeve Caroline, Jacobi Catharina E, de Bock Geertruida H, Devilee Peter, Tollenaar Rob AEM, Brekelmans Cecile TM, van Houwelingen Johannes C

Publikováno v: BMC Cancer, Vol 8, Iss 1, p 203 (2008)

Abstract Background An increased risk of breast cancer for relatives of breast cancer patients has been demonstrated in many studies, and having a relative diagnosed with breast cancer at an early age is an indication for breast cancer screening. Thi

Externí odkaz: https://doaj.org/article/b56947af2a6241128583e6e312c78713

Hoeveel klinische geneesmiddelenstudies worden uiteindelijk gepubliceerd?. Fase 1-studies blijven achter in aantal publicaties

Autor: Den Bogert, C. A., Souverein, Patrick C., Brekelmans, Cecile T. M., Janssen, Susan W. J., Koeter, Gerard H., Leufkens, H. G. M., Lex Bouter

Publikováno v: Nederlands Tijdschrift voor Geneeskunde, 161(28):d1498. Bohn Stafleu van Loghum
Van Den Bogert, C A, Souverein, P C, Brekelmans, C T M, Janssen, S W J, Koeter, G H, Leufkens, H G M & Bouter, L M 2017, ' Hoeveel klinische geneesmiddelenstudies worden uiteindelijk gepubliceerd?. Fase 1-studies blijven achter in aantal publicaties ', Nederlands Tijdschrift voor Geneeskunde, vol. 161, no. 28, d1498 .
Vrije Universiteit Amsterdam

The objective of this study was to investigate the occurrence and determinants of nonpublication of clinical drug trials in the Netherlands. All clinical drug trials reviewed by the 28 Institutional Review Boards (IRBs) in the Netherlands in 2007 wer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d9652e05211d6217c60dc76f5dc1653b
https://research.vumc.nl/en/publications/2cd103bb-c8cf-48f0-b0e1-7dc733c03edb